BioSpace News Archive

Business

Illumina and Deerfield Team Up to Utilize AI, Genomics in Drug Development

Illumina and Deerfield Management have entered into a five-year partnership to apply a genetic-led approach to the discovery and development of novel therapies.

May 5, 2022
·
2 min read
·
Hayley Shasteen
Business

CinCor’s Terry Coelho is Building Bridges Between Finance & Business Units

For Terry Coelho, being CFO is about becoming a trusted strategic partner across the business. It’s about building bridges.

May 5, 2022
·
4 min read
·
Gail Dutton
Drug Development

Novartis Stops Production of Cancer Drugs Over Quality Concerns

Novartis announced on Thursday that it will be temporarily and voluntarily suspending the production of its cancer therapeutics Lutathera and Pluvicto at facilities in Italy and New Jersey.

May 5, 2022
·
2 min read
·
Hayley Shasteen
Drug Development

Amylyx Augments Case for ALS Drug Ahead of PDUFA Date

A post hoc analysis of data from the Phase II CENTAUR study showed a 10.6-month longer median survival duration for AMX0035 participants, Amylyx announced Thursday.

May 5, 2022
·
5 min read
·
Alex Keown
Drug Development

Vertex Flexes Clinical Muscle, Moves Beyond Cystic Fibrosis

With a robust pipeline, Vertex is moving beyond its market dominance in cystic fibrosis and laying claim to multiple markets in diabetes, pain, kidney disease and sickle cell disease.

May 5, 2022
·
4 min read
·
Alex Keown
Addex Reports Q1 2022 Financial Results

Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, reported financial results for the quarter ended March 31, 2022.

May 5, 2022
·
6 min read
Business

Valneva Reports Q1 2022 Results and Provides Corporate Updates

Valneva SE, a specialty vaccine company, reported its first quarter financial results ending March 31, 2022 and provided corporate updates.

May 5, 2022
·
18 min read
Business

argenx Reports First Quarter 2022 Financial Results and Provides Business Update

argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, reported financial results for the first quarter 2022 and provided a business update.

May 5, 2022
·
14 min read
Drug Development

argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia

argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced positive data from the Phase 3 ADVANCE trial of VYVGART® in adults with primary ITP.

May 5, 2022
·
13 min read
Dental Milling Machine Market: Rise in occurrence of dental disorders to drive the market

Albany NY, United States: Dental milling machine is utilized to design and make simulated dental prosthetics.

May 5, 2022
·
6 min read